Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for MeiraGTx Holdings PLC (MGTX : NSDQ)

• Company Description    MeiraGTx Holdings plc focuses on operating as a holding company for MeiraGTx Limited which operates as a clinical stage gene therapy company. It develops novel gene therapy treatments for inherited and acquired disorders. The company's product pipeline consists of AAV-CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1, AAV-AQP1 and AAV-UPF1 which are in clinical stage. MeiraGTx Holdings plc is based in New York. Number of Employees: 381

• Price / Volume Information    Yesterday's Closing Price: $7.95 Daily Weekly Monthly 20 Day Moving Average: 450,459 shares Shares Outstanding: 80.49 (millions) Market Capitalization: $639.90 (millions) Beta: 1.38 52 Week High: $9.73 52 Week Low: $4.55 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -7.56% -7.40% 12 Week -9.25% -10.71% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 655 THIRD AVENUE SUITE 1115 - NEW YORK,NY 10017 USA ph: 646-860-7985 fax: - investors@meiragtx.com http://www.meiragtx.com

• General Corporate Information    Officers Alexandria Forbes - Chief Executive Officer;President and Director Keith R. Harris - Chairman of the Board and Director Richard Giroux - Chief Financial Officer Ellen Hukkelhoven - Director Lord Mendoza - Director Peer Information MeiraGTx Holdings PLC (CORR.) MeiraGTx Holdings PLC (RSPI) MeiraGTx Holdings PLC (CGXP) MeiraGTx Holdings PLC (BGEN) MeiraGTx Holdings PLC (GTBP) MeiraGTx Holdings PLC (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: G59665102 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/12/26 Share - Related Items Shares Outstanding: 80.49 Most Recent Split Date: (:1) Beta: 1.38 Market Capitalization: $639.90 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.59 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.04 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 23.34 EPS Growth vs. Year Ago Period: -14.81% vs. Previous Quarter: -29.17% Sales Growth vs. Year Ago Period: -96.24% vs. Previous Quarter: -88.89% ROE 12/31/25 - - 09/30/25 - -1,065.47 06/30/25 - -314.44 ROA 12/31/25 - - 09/30/25 - -76.51 06/30/25 - -63.28 Current Ratio 12/31/25 - - 09/30/25 - 0.22 06/30/25 - 0.88 Quick Ratio 12/31/25 - - 09/30/25 - 0.22 06/30/25 - 0.88 Operating Margin 12/31/25 - - 09/30/25 - -615.27 06/30/25 - -413.85 Net Margin 12/31/25 - - 09/30/25 - -615.27 06/30/25 - -415.39 Pre-Tax Margin 12/31/25 - - 09/30/25 - -615.27 06/30/25 - -415.39 Book Value 12/31/25 - - 09/30/25 - -0.50 06/30/25 - 0.04 Inventory Turnover 12/31/25 - - 09/30/25 - 49.53 06/30/25 - 85.28 Debt-to-Equity 12/31/25 - - 09/30/25 - - 06/30/25 - 26.29 Debt-to-Capital 12/31/25 - - 09/30/25 - - 06/30/25 - 96.34

Powered by Zacks Investment Research ©